# A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis

> **NCT00505037** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 156 (actual)

## Conditions studied

- Hyperphosphatemia
- Chronic Kidney Disease

## Interventions

- **DRUG:** ASP1585
- **DRUG:** Placebo
- **DRUG:** Sevelamer hydrochloride

## Key facts

- **NCT ID:** NCT00505037
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 156 (ACTUAL)
- **Last updated:** 2011-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00505037

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00505037, "A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00505037. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*